(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-[2-(2-hydroxyethoxy)ethoxy]cyclopentane-1,2-diol | 1529812-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-[2-(2-hydroxyethoxy)ethoxy]cyclopentane-1,2-diol
• CAS: 1529812-22-3
• 化学式: C₂₅H₃₂F₂N₆O₅S
• 分子量: 566.629
• InChiKey: PYHVVDDESMRCEM-FYEBJQQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  173
• 氢给体数：
  4
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  异亚丙基替卡格雷 在 盐酸 、 锂硼氢 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-[2-(2-hydroxyethoxy)ethoxy]cyclopentane-1,2-diol
  参考文献：
  名称：

  Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists

  摘要：

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.055

文献信息

• Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists
  作者：Wangyang Tu、Jiang Fan、Haitang Zhang、Guoji Xu、Zhiwei Liu、Jian Qu、Fanglong Yang、Lei Zhang、Tianyu Luan、Jijun Yuan、Aishen Gong、Jun Feng、Piaoyang Sun、Qing Dong

  DOI：10.1016/j.bmcl.2013.11.055

  日期：2014.1

  In this Letter we describe SAR investigation on the cyclopentyl-triazolol-pyrimidine scaffold in pursuit of new oral P2Y(12) inhibitors. Different synthetic routes were developed for variations at the cyclopentyl core. Optimization finally led to compound 2d which was advanced into preclinical development based on better potency and safety profile in comparison to ticagrelor. (C) 2013 Elsevier Ltd. All rights reserved.